Repeat doses of ipilimumab can restore a complete remission in patients with advanced blood cancers who relapse after allogeneic hematopoietic stem cell transplant (alloHSCT).
Case Reports Show an Association Between Immune Checkpoint Inhibitors and Risk for Rheumatologic DisordersJuly 11, 2016
A small number of patients with cancer treated with immune checkpoint inhibitors may have higher-than-usual risk of developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a case report on 13 patients has shown.
Final analysis of data from the phase 3 KEYNOTE-006 presented at the ASCO 2016 Annual Meeting confirm the superiority of pembrolizumab over ipilimumab for advanced melanoma.
An international study demonstrated that ipilimumab improves the relapse-free survival of patients with advanced stage melanoma who are rendered free of disease surgically but at high risk for relapse.
The adverse event profile of nivolumab with or without ipilimumab in patients with glioblastoma was encouraging.
Adjuvant ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence, but is also associated with a high rate of adverse events.
Almost half of patients with blood cancer who had relapsed following allogeneic stem cell transplantation benefitted from treatment with the immune checkpoint blocker ipilimumab.
Pairing ipilimumab with sargramostim gives patients about five extra months survival time for patients with advanced melanoma, researchers report.
Among patients with advanced melanoma, presence of higher levels of the protein VEGF in blood was associated with poor response to treatment with the immunotherapy ipilimumab.
High pretreatment VEGF levels have been linked to lower survival after ipilimumab treatment.
Findings from a phase I study of concurrent ipilimumab and nivolumab for advanced melanoma
A new study suggests radiotherapy may hold clinical promise for the control of local lymph node bed recurrence of malignant melanoma.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Recurrence Score Appears To Be Driving Personalized Treatment for Breast Cancer
- Smoking-related Cancer Deaths Highest in Southern United States
- Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered
- The Bounty of Failure: A Well-Versed Nursing Experience
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|